Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for GILD
100.30
-0.81 (-0.80%)
Nov 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 98.37 - 101.55
52 week 63.50 - 116.83
Open 101.25
Vol / Avg. 11.54M/16.54M
Mkt cap 151.32B
P/E 17.74
Div/yield     -
EPS 5.65
Shares 1.51B
Beta 0.74
Inst. own 87%
Feb 2, 2015
Q4 2014 Gilead Sciences Inc Earnings Release (Estimated) - 4:05PM EST - Add to calendar
Dec 3, 2014
Gilead Sciences Inc at Piper Jaffray Healthcare Conference - 9:30AM EST - Add to calendar
Dec 2, 2014
Gilead Sciences Inc at NASDAQ OMX Investor Program - 6:15AM EST - Add to calendar
Oct 28, 2014
Q3 2014 Gilead Sciences Inc Earnings Call - Webcast
Oct 28, 2014
Q3 2014 Gilead Sciences Inc Earnings Release
Sep 9, 2014
Gilead Sciences Inc at Morgan Stanley Healthcare Conference
Sep 4, 2014
Gilead Sciences Inc at Robert W. Baird & Co. Inc Health Care Conference
Sep 3, 2014
Gilead Sciences Inc at Citi Biotech Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 45.09% 27.29%
Operating margin 57.59% 40.39%
EBITD margin - 43.46%
Return on average assets 36.39% 13.98%
Return on average equity 73.88% 29.75%
Employees 6,100 -
CDP Score - -

Address

333 LAKESIDE DR
FOSTER CITY, CA 94404
United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

Officers and directors

John C. Martin Ph.D. Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
John F. Milligan Ph.D. President, Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul R. Carter Executive Vice President - Commercial Operations
Age: 53
Bio & Compensation  - Reuters
John F. Cogan Jr., P Lead Independent Director
Bio & Compensation  - Reuters
Etienne F. Davignon Independent Director
Age: 81
Bio & Compensation  - Reuters
Carla A. Hills Independent Director
Age: 80
Bio & Compensation  - Reuters
Kevin E. Lofton Independent Director
Age: 59
Bio & Compensation  - Reuters